Replies to post #141008 on PharmaCyte Biotech Inc (PMCB)

[Daphnis]

NICE and exactly

[livendi]

They didn’t now did they. Fda can’t stop a company from submitting ind they can only react after submission. What did fda do once ind submission happened. They rejected it 3 days in for incomplete information and gave a list so long that they will never entertain Pmcb again because they know its a SCAM so fda didn’t entertain a scam now did they. Hold will never ever be lifted per mega slime kw in the 10q where he can’t lie or pay someone to lie for him so fda didn’t entertain this pos pump and dump scam lead by mega slime kw who was a defendant in 2 previous fraud cases now did they. Lol. BANKRUPTCY coming and kw 3rd fraud case onnce bankruptcy comes. U are right u do what u do and ill do what i do. Why would fda entertain a scam huh. I got news for u. They didn’t. God bless all

[$Pistol Pete$]

$PMCB so when are they going to do the reverse split? Or are they just increase another 5b shares into the market

https://www.otcmarkets.com/stock/PMCB/security

[The grateful smiths]

They didn’t entertain the scam. They rejected it within 3 days of submittal after these bozos spent years and years and years and millions on salaries, not r and d preparing what supposed to be a perfect specimen of IND application. Instead we got excuses, lies and more misdirection. The FDA saw right through this sham and if investors had any experience in this field they would smell the scam form a mile away.

[$Pistol Pete$]

What is happening to the cannabis and covid test kit? They find all kind of pump material to get in and pump the stock so they can dump more shares isn’t it?

[DragonBear]

Why would the FDA entertain a scam?

The FDA doesn't judge business models.

Outside of eye-of-newt to cure Covid, the FDA will review anything "reasonable" submitted to them.

The FDA also can not predict the plans of a biotech/Pharma. PMCB is not going to get a Phase 2b CT approved. However, maybe some year Kenny will start at Phase 1. And when that fails using PFS as an endpt, then Kenny might be able to switch to a trial for palliative treatment. Which is difficult to get marketing approval for in this instance. In any case the pre-clinical tests required for a Phase 1, or palliative treatment CT, would be the same as they are today. Or Kenny may have already decided he'll just PR pump for another 2 yrs, and then walk away. In all scenarios the FDA isn't in the business of predicting what future direction a company might take with its proposed treatment. Instead the FDA tells the company of any pre-clinical and/or protocol deficiencies in a submitted IND. There's nothing to "entertain".